Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation

On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.

Citation:
Carlson SJ, McKenzie L, Roberts L, Blyth CC, Attwell K. Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation. Vaccine. 2021.

Keywords:
Adult; Australia; Covid-19 vaccines; Health Knowledge, Attitudes, Practice; Health policy; Intention; Vaccination

Abstract:
On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.